tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2014-1-39-46tumors-5Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL REPORTSАДЪЮВАНТНАЯ ТЕРАПИЯ ПАЦИЕНТОВ С ГАСТРОИНТЕСТИНАЛЬНЫМИ СТРОМАЛЬНЫМИ ОПУХОЛЯМИ: СТРАТИФИКАЦИЯ БОЛЬНЫХ ПО ГРУППАМ РИСКАAdjuvant treatment of patients with gastrointestinal stromal tumors: stratification of patients into risk groupКорниловаА. Г.KornilovaA. G.

онколог МУЗ Подольская городская клиническая больница, аспирант кафедрыонкологии и торакальной хирургии 

doc.kornilova@mail.ruМордановС. В.MordanovS. V.

к.м.н, заведующий лабораторией медицинской генетики

ОксенюкО. С.OksenyukO. S.

к. м.н, руководитель биохимического отдела

КогонияЛ. М.KogoniyaL. M.

д.м.н., профессор кафедры онкологии и торакальной хирургии

lali51@yandex.ruФУВ ГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М. Ф. Владимирского»Russian FederationГБОУ ВПО «Ростовский государственный медицинский университет» МЗ РФRussian FederationРостовский ЦНИЛRussian FederationФУВ ГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М. Ф. Владимирского»Russian Federation201419052015013946Copyright © Корнилова А.Г., Морданов С.В., Оксенюк О.С., Когония Л.М., 20152015Корнилова А.Г., Морданов С.В., Оксенюк О.С., Когония Л.М.Kornilova A.G., Mordanov S.V., Oksenyuk O.S., Kogoniya L.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/5

Опыт проведения адъювантной терапии больных с гастроинтестинальными стромальными опухолями (ГИСО) продемонстрировал свою высокую эффективность, позволив увеличить безрецидивную выживаемость пациентов почти в 2 раза. В настоящее время пациенты группы низкого риска после проведения радикального хирургического лечения остаются под динамическим наблюдением, больным ГИСО группы умеренного риска рекомендовано проведение адъювантной терапии иматинибом в течение 1 года, высокого риска — 3 лет. В статье представлен обзор наиболее значимых прогностических факторов, анализ которых позволит клиническому онкологу наиболее точно стратифицировать больных по группам риска и тем самым увеличить эффективность проводимой таргетной терапии.

The experience of adjuvant treatment of patients with gastrointestinal stromal tumors (GIST) demonstrated its high efficiency, allowing to increase disease-free survival by almost 2 times. Currently, low-risk patients after radical surgical treatment need dynamic observation, patients with moderate-risk recommended to receive adjuvant treatment with imatinib for 1 year and high risk patients – for 3 years. This article presents an overview of the most important prognostic factors, the analysis of which will allow clinical oncologist to stratify patients into risk groups more accurately and thus increase the effectiveness of the targeted therapy.

гастроинтестинальные стромальные опухолиадъювантная терапиягруппы рискаиматиниб.gastrointestinal stromal tumorsGISTadjuvant therapyrisk groupsimatinibReferencesMazur M. T., Clark H. B. Gastric stromal tumors: Reappraisal of histogenesis. Am J Surg. Pathol. — 1983; 7: 507–519.Mazur M. T., Clark H. B. Gastric stromal tumors: Reappraisal of histogenesis. Am J Surg. Pathol. — 1983; 7: 507–519.Sarlomo-Rikala M., Kovatich A. J., Barusevicius A. et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol. — l998; 11 (8): 728–34.Sarlomo-Rikala M., Kovatich A. J., Barusevicius A. et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol. — l998; 11 (8): 728–34.Miettinen M., Lasota J. Gastrointestinal stromal tumours: review on morphology, molecular pathology, prognosis, and dif ferential diagnosis. Arch Pathol Lab Med. — 2006; 130: 1466–1478.Miettinen M., Lasota J. Gastrointestinal stromal tumours: review on morphology, molecular pathology, prognosis, and dif ferential diagnosis. Arch Pathol Lab Med. — 2006; 130: 1466–1478.Kawanowa K., Sakuma Y., Sakurai S. et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Human Pathol. — 2006; 37 (12): 1527–1535.Kawanowa K., Sakuma Y., Sakurai S. et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Human Pathol. — 2006; 37 (12): 1527–1535.Agaimy A., Wünsch P. H., Hofstaedter F. et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol. — 2007; 31 (1): 113–20.Agaimy A., Wünsch P. H., Hofstaedter F. et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol. — 2007; 31 (1): 113–20.Ng E. H., Pollock R. E., Munsell M. F. et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg. — 1992; 215 (1): 68–77.Ng E. H., Pollock R. E., Munsell M. F. et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg. — 1992; 215 (1): 68–77.De Matteo R., Lewis J., Leung D., et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surgery. — 2000; 231: 51–58.De Matteo R., Lewis J., Leung D., et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surgery. — 2000; 231: 51–58.Dougherty M. J., Compton C., Talbert M., Wood W. C. Sarcomas of the gastrointestinal tract. Separation into favorable and unfavorable prognostic groups by mitotic count. Ann Surg. —1991; 214 (5): 569–74.Dougherty M. J., Compton C., Talbert M., Wood W. C. Sarcomas of the gastrointestinal tract. Separation into favorable and unfavorable prognostic groups by mitotic count. Ann Surg. —1991; 214 (5): 569–74.Plaat B. E., Hollema H., Molenaar W. M. et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences inclinical outcome and expression of multidrug resistance proteins. J Clin Oncol. — 2000; 18 (18): 3211–20.Plaat B. E., Hollema H., Molenaar W. M. et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences inclinical outcome and expression of multidrug resistance proteins. J Clin Oncol. — 2000; 18 (18): 3211–20.Mudan S., Conlon K., Woodruff J. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Canсer. — 2000; 88: 66–74.Mudan S., Conlon K., Woodruff J. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Canсer. — 2000; 88: 66–74.Antman K., Crowley J., Balcerzak S. et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced sof t tissue and bone sarcomas. J Clin Oncol. — 1993; 11 (7): 1276–85.Antman K., Crowley J., Balcerzak S. et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced sof t tissue and bone sarcomas. J Clin Oncol. — 1993; 11 (7): 1276–85.Zalupski M., Metch B., Balcerzak S. et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Nat Cancer Inst. — 1991; 83 (13): 926–32.Zalupski M., Metch B., Balcerzak S. et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Nat Cancer Inst. — 1991; 83 (13): 926–32.Pidhorecky I., Cheney R. T., Kraybill W. G. et al. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol. — 2000; 7 (9): 705–12.Pidhorecky I., Cheney R. T., Kraybill W. G. et al. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol. — 2000; 7 (9): 705–12.Hirota S., Isozaki K., Moriyama Y. et al. Gain-function mutations of c-kit in human gastrointestinal stromal tumors. Science. — 1998; 279: 577–580.Hirota S., Isozaki K., Moriyama Y. et al. Gain-function mutations of c-kit in human gastrointestinal stromal tumors. Science. — 1998; 279: 577–580.Kindblom L. G., Remotti H. E., Aldenborg F. et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenot ypic characteristics of the interstitial cells of Cajal. Am J Pathol. — 1998; 152 (5): 1259–69.Kindblom L. G., Remotti H. E., Aldenborg F. et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenot ypic characteristics of the interstitial cells of Cajal. Am J Pathol. — 1998; 152 (5): 1259–69.Van den Abbelle A. D. 18-FDG-PET provides early evidence of biological response to STI-571 in patients with malignant gastrointestinal stromal tumors. Proc Am Soc Clin Oncol. — 2001; 20: 362.Van den Abbelle A. D. 18-FDG-PET provides early evidence of biological response to STI-571 in patients with malignant gastrointestinal stromal tumors. Proc Am Soc Clin Oncol. — 2001; 20: 362.Van Oosterom A. T., Judson I. R., Verweij J. et al. Update of phase I study of imatinib (STI 571) in advanced soft tissue sarcomas and gastrointestinal stromal tumours: a report of the EORT C Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer. — 2002; 38: 83–87.Van Oosterom A. T., Judson I. R., Verweij J. et al. Update of phase I study of imatinib (STI 571) in advanced soft tissue sarcomas and gastrointestinal stromal tumours: a report of the EORT C Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer. — 2002; 38: 83–87.Blackstein M. E., Corless C. L., Ballman K. V. et al. Risk assessment for tumor recurrence af ter surgical resection of localized primary gastrointestinal stromal tumor: North American Intergroup phase III trial ACOSOG Z9001. GI ASCO. — 2010: 6.Blackstein M. E., Corless C. L., Ballman K. V. et al. Risk assessment for tumor recurrence af ter surgical resection of localized primary gastrointestinal stromal tumor: North American Intergroup phase III trial ACOSOG Z9001. GI ASCO. — 2010: 6.Znah W. H. Efficacy and safety of adjuvant post-surgical therapy with imatinib in patients with high risk of relapsing GIST. A SCO 2007, Abstr. 10045.Znah W. H. Efficacy and safety of adjuvant post-surgical therapy with imatinib in patients with high risk of relapsing GIST. A SCO 2007, Abstr. 10045.European Organisation for Research and T reatment of Cancer. EORTC 62024 study protocol. Phase III randomized study of adjuvant imatinib mesylate versus observation only in patients with completely resected localized gastrointestinal stromal tumor at intermediate- or high-risk of relapse. A vailable at: http://www. cancer.gov/clinicaltrials/EORTC-62024European Organisation for Research and T reatment of Cancer. EORTC 62024 study protocol. Phase III randomized study of adjuvant imatinib mesylate versus observation only in patients with completely resected localized gastrointestinal stromal tumor at intermediate- or high-risk of relapse. A vailable at: http://www. cancer.gov/clinicaltrials/EORTC-62024Joensuu H., Eriksson M., Sundby H. K. et al. One vs three years of adjuvant imatinib for operable GIST: a randomized trial. JAMA. — 2012; 307 (12): 1265–72.Joensuu H., Eriksson M., Sundby H. K. et al. One vs three years of adjuvant imatinib for operable GIST: a randomized trial. JAMA. — 2012; 307 (12): 1265–72.ESMO Update Clinical Practice Guidelines. Ann of Oncol. — 2012; 23, Supplement 7.ESMO Update Clinical Practice Guidelines. Ann of Oncol. — 2012; 23, Supplement 7.Singer S., Rubin B. P., Lux M. L. et al. Prognostic value of KIT mutation t ype, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol. — 2002; 20 (18): 3898–905.Singer S., Rubin B. P., Lux M. L. et al. Prognostic value of KIT mutation t ype, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol. — 2002; 20 (18): 3898–905.Miettinen M., Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. — 2001; 438 (1): 1–12.Miettinen M., Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. — 2001; 438 (1): 1–12.Guillou L., Coindre J. M. Prognostic factors in sof t tissue sarcoma in the adult. Ann Pathol. — 1997; 17 (6): 375–377.Guillou L., Coindre J. M. Prognostic factors in sof t tissue sarcoma in the adult. Ann Pathol. — 1997; 17 (6): 375–377.De Matteo R. P., Gold J. S., Saran L. et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primar y gastrointestinal stromal tumor (GIST). Cancer. — 2008; 112: 608–615.De Matteo R. P., Gold J. S., Saran L. et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primar y gastrointestinal stromal tumor (GIST). Cancer. — 2008; 112: 608–615.ESMO Clinical Recommendations for diagnosis, treatment and follow-up. — 2010: 147–153.ESMO Clinical Recommendations for diagnosis, treatment and follow-up. — 2010: 147–153.Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. — 2008; 39 (10): 1411–1419.Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. — 2008; 39 (10): 1411–1419.Gold J. S., Gönen M., Gutiérrez A. et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. — 2009; 10 (11): 1045–52.Gold J. S., Gönen M., Gutiérrez A. et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. — 2009; 10 (11): 1045–52.Belev B., Brčić I., Prejac J. et al. Role of Ki-67 as a prognostic factor in gastrointestinal stromal tumors. World J Gastroenterol. — 2013; 19 (4): 523–7.Belev B., Brčić I., Prejac J. et al. Role of Ki-67 as a prognostic factor in gastrointestinal stromal tumors. World J Gastroenterol. — 2013; 19 (4): 523–7.Miettinen M., El-Rifai W. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol. — 2002; 33: 478–483.Miettinen M., El-Rifai W. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol. — 2002; 33: 478–483.Miettinen M., Makhlouf H. R., Sobin L. H. et al. Gastrointestinal stromal tumors (GISTs) of the jejunum and ileum: a clinicopathologic, immunohistochemical and molecular genetic study of 906 cases prior to imatinib with longterm follow-up. Am. J Surg. Pathol. — 2006; 30: 477–489.Miettinen M., Makhlouf H. R., Sobin L. H. et al. Gastrointestinal stromal tumors (GISTs) of the jejunum and ileum: a clinicopathologic, immunohistochemical and molecular genetic study of 906 cases prior to imatinib with longterm follow-up. Am. J Surg. Pathol. — 2006; 30: 477–489.Miettinen M., Fetsch J. F., Sobin L. H. Gastrointestinal stromal tumors in patients with neurofibromatosis: a clinicopathologic and molecular genetic study of 45 cases. Am. J. Surg. Pathol. — 2006; 30: 90–96.Miettinen M., Fetsch J. F., Sobin L. H. Gastrointestinal stromal tumors in patients with neurofibromatosis: a clinicopathologic and molecular genetic study of 45 cases. Am. J. Surg. Pathol. — 2006; 30: 90–96.Rutkowski P., Nowecki Z., Nyckowski P. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol. — 2006; 93: 304–311.Rutkowski P., Nowecki Z., Nyckowski P. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol. — 2006; 93: 304–311.Tarn C., Merkel E., Canutescu A. A. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling. Clin. Cancer Res. — 2005; 11: 3668–3677.Tarn C., Merkel E., Canutescu A. A. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling. Clin. Cancer Res. — 2005; 11: 3668–3677.Lasota J., Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Department of Soft Tissue Pathology, Armed Forces Institute of Pathology, Washington DC. USA Histopathology. — 2008: 4–16.Lasota J., Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Department of Soft Tissue Pathology, Armed Forces Institute of Pathology, Washington DC. USA Histopathology. — 2008: 4–16.Никулин М. П., Стилиди И. С. Гастроинтестинальные стромальные опухоли (ГИСО). Эпидемиология, диагностика, современные подходы к лечению. Современная онкология. Экстра выпуск. — 2007: 3–50.Никулин М. П., Стилиди И. С. Гастроинтестинальные стромальные опухоли (ГИСО). Эпидемиология, диагностика, современные подходы к лечению. Современная онкология. Экстра выпуск. — 2007: 3–50.Benjamin R. S., Rankin C., Fletcher C. For the Sarcoma Intergroup. Phase III dose-randomized study of imatinib mesylate (ST1571) for GIST: Intergroup S0033 early results. Proc Am Soc Clin Oncol. — 2003; 22: 814.Benjamin R. S., Rankin C., Fletcher C. For the Sarcoma Intergroup. Phase III dose-randomized study of imatinib mesylate (ST1571) for GIST: Intergroup S0033 early results. Proc Am Soc Clin Oncol. — 2003; 22: 814.Raut C. P., Posner M., Desai J. et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J. Clin. Oncol. — 2006; 15: 2325–31.Raut C. P., Posner M., Desai J. et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J. Clin. Oncol. — 2006; 15: 2325–31.Miettinen M., Sobin L. H., Lasota J. Gastrointestinal stromal tumors of the stomach — a clinicopathologic, immunohistochemical and molecular genetic study of 1756 cases with long-term follow-up. Am. J. Surg. Pathol. — 2005; 29: 52–68.Miettinen M., Sobin L. H., Lasota J. Gastrointestinal stromal tumors of the stomach — a clinicopathologic, immunohistochemical and molecular genetic study of 1756 cases with long-term follow-up. Am. J. Surg. Pathol. — 2005; 29: 52–68.Miettinen M., Lasota J. Gastrointestinal stromal tumors: definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol. J. Pathol. — 2003; 54: 3–24.Miettinen M., Lasota J. Gastrointestinal stromal tumors: definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol. J. Pathol. — 2003; 54: 3–24.Снигур П. В., Анурова О. А. Стромальные опухоли двенадцатиперстной кишки. Хирургия. — 2003; 11: 46–48.Снигур П. В., Анурова О. А. Стромальные опухоли двенадцатиперстной кишки. Хирургия. — 2003; 11: 46–48.Corless C. L., Schroeder A., Griffith D. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivit y to imatinib. J. Clin. Oncol. — 2005; 23: 5357–5364.Corless C. L., Schroeder A., Griffith D. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivit y to imatinib. J. Clin. Oncol. — 2005; 23: 5357–5364.Daum O., Grossmann P., Vanecek T. Diagnostic morphological features of PDGFRA-mutated gastrointestinal stromal tumors: molecular genetic and histologic analysis of 60 cases of gastric gastrointestinal stromal tumors. Ann. Diagn. Pathol. — 2007; 11: 27–33.Daum O., Grossmann P., Vanecek T. Diagnostic morphological features of PDGFRA-mutated gastrointestinal stromal tumors: molecular genetic and histologic analysis of 60 cases of gastric gastrointestinal stromal tumors. Ann. Diagn. Pathol. — 2007; 11: 27–33.Martin J., Poveda J., Llombart-Bosch A. Deletions affecting codons 557–558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J. Clin. Oncol. — 2005; 23: 6190–6198.Martin J., Poveda J., Llombart-Bosch A. Deletions affecting codons 557–558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J. Clin. Oncol. — 2005; 23: 6190–6198.Hassan I., You Y. N., Shyyan R. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann Surg Oncol. — 2008; 15 (1): 52–9.Hassan I., You Y. N., Shyyan R. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann Surg Oncol. — 2008; 15 (1): 52–9.

The authors declare that there are no conflicts of interest present.